Product News
FDA Accepted PD-L1 Inhibitor Durvalumab for the Treatment of Endometrial Cancer
On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency.
Product News
Beckman Coulter Life Sciences and Illumina Accelerate Oncology Research With Launch of TruSight Oncology 500 DNA/RNA Application
Assay automation makes cutting-edge research more accessible to labs.
Product News
Transgene Strengthens Its Balance Sheet via Equity Conversion of Current Account Advance From TSGH
Transgene (Euronext Paris: TNG), announces the conversion into equity of 32,999,999.57 euros of debt, drawn down under the outstanding current account advance with its majority shareholder TSGH.
Product News
Bio-Rad Launches Celselect Slides 2.0 To Advance Rare Cell and Circulating Tumor Cell Enrichment for Cancer Research
New Celselect slides™ design increases efficiency of circulating tumor cell capture from liquid biopsy samples for enumeration and downstream applications.
Product News
Association for Molecular Pathology Publishes Evidence-Based Recommendations for Tumor Mutational Burden Testing
AMP published a set of evidence-based recommendations for the analytical validation and reporting of tumor mutational burden (TMB) testing as a potential predictive biomarker for immune checkpoint inhibitor (ICI) therapies.
Product News
Estonia Develops Personalized CAR-T Cell Therapy for Blood Cancer Patients
The Tartu University Hospital, North Estonia Medical Centre, and Icosagen have joined forces to develop and introduce an innovative personalized cell therapy (CAR-T cell therapy) for patients in Estonia.
Advertisement
